Company Profile

Orgenesis is a pioneering global biotech company which is unlocking the full potential of personalized therapies and closed processing systems through its Cell & Gene Therapy Biotech Platform, with the ultimate aim of providing life changing treatments at the point of care (POCare) to large numbers of patients at low cost. The Platform consists of: (a) POCare Therapeutics, a pipeline of licensed cell and gene therapies (CGTs), and proprietary scientific knowhow; (b) POCare Technologies, a suite of proprietary and in-licensed technologies which are engineered to create customized processing systems for affordable point of care therapies; and (c) POCare Network, a collaborative, international ecosystem of leading research institutes and hospitals committed to clinical development and supply of CGTs at the point of care. By combining science, technologies and a collaborative network, Orgenesis is able to identify the most promising new therapies and provide a pathway for them to reach patients more quickly, more efficiently and at scale, thereby unlocking the power of cell and gene therapy for all.

Latest Quarterly Results

Q3 2020

Quarter Ended Sep 30, 2020

Latest 10-K

View Latest 10-K

Stock Information

View Detailed Stock Data

Orgenesis Inc.

Nasdaq: ORGS Symbol
Market Cap
Day Range
52 WK Range

IR Contact Information

Investor Relations Crescendo Communications, LLC
David K. Waldman
T: (212) 671-1020

Media & Corporate Inquiries Image Box Communications
Neil Hunter

Transfer Agent Securities Transfer Corporation
2591 Dallas Parkway
Suite 102
Frisco, TX 75034
T: 469-633-0101
F: 469-633-0088